Dr. Nicholas J. Procaccini, MD
Gastroenterology (Gastroenterology Physician)
1221 Madison St Ste 1220
Seattle, WA 98104
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 182
Licensed in Washington since 2009, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Virginia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
WA license MD60078001 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Overlake Hospital Medical Center & Clinics Bellevue, WA
Medical groups
- Washington Gastroenterology PLLC (143 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 602
- Patients’ average age
- 75
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Seattle, WA | 26 |
| Omeprazole Other prescribers in Seattle, WA | 24 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Seattle, WA | 17 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Seattle, WA | 15 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Seattle, WA | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 83 payments worth $1,968 in total to this clinician.
| AbbVie Inc. | $467 |
|---|---|
| Janssen Biotech, Inc. | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | $271 |
| Madrigal Pharmaceuticals | $180 |
| Ipsen Biopharmaceuticals, Inc | $175 |
| Phathom Pharmaceuticals, Inc. | $129 |
| Aimmune Therapeutics, Inc. | $101 |
| Genzyme Corporation | $59.88 |
| Food and Beverage | $1,968 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $61,185 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Active, not recruiting · NCT04232553 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company · Completed · NCT05767021 - M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028 - LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company · Recruiting · NCT07186101
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.